The impact of multi-drug resistant Pseudomonas aeruginosa infections on acute pancreatitis patients
- PMID: 37217844
- PMCID: PMC10201707
- DOI: 10.1186/s12879-023-08230-y
The impact of multi-drug resistant Pseudomonas aeruginosa infections on acute pancreatitis patients
Abstract
Introduction: Acute pancreatitis (AP) accounts for a high proportion of digestive diseases worldwide and has a high risk of infection. Pseudomonas aeruginosa, a common pathogen of hospital infections, has been observed to increase the resistance rate to several antibiotics, causing difficulties in treatments. Our study aims to investigate the impact of the multi-drug resistant Pseudomonas aeruginosa (MDR-PA) infections on AP patients.
Methods: At two Chinese tertiary referral centers for AP patients infected with MDR-PA, a retrospective case-control study with a 1:2 case-control ratio was performed. Comparisons were preformed between with/without MDR-PA infections and different drug-resistance of MDR-PA infections patients, respectively. Independent risk factors of overall mortality were assessed via univariate and multivariate binary logistic regression analyses, and the distribution and antibiotic resistant rates of strains were described.
Results: Mortality in AP patients with MDR-PA infections was significantly higher than in those without MDR-PA infections (7 (30.4%) vs. 4 (8.7%), P = 0.048). The rate of prophylactic use of carbapenem for 3 days (0 vs. 50%, P = 0.019) and the incidence rate of multiple organ failure (MOF) (0 vs. 57.1%, P = 0.018) were remarkably higher in the carbapenem-resistant Pseudomonas aeruginosa group compared with the carbapenem-sensitive Pseudomonas aeruginosa group. In the multivariate analysis, the severe categories of AP (OR = 13.624, 95% CIs = 1.567-118.491, P = 0.018) and MDR-PA infections (OR = 4.788, 95% CIs = 1.107-20.709, P = 0.036) were independent risk factors for mortality. The resistance rates of MDR-PA strains were low for amikacin (7.4%), tobramycin (3.7%), and gentamicin (18.5%). The resistance rates of MDR-PA strains to imipenem and meropenem were up to, 51.9% and 55.6%, respectively.
Conclusion: In AP patients, severe categories of AP and MDR-PA infections were both independent risk factors for mortality. Inappropriate use of carbapenem antibiotics and MOF were related to carbapenem-resistant Pseudomonas aeruginosa infections. Amikacin, tobramycin, and gentamicin are recommended for the treatment of AP patients with MDR-PA infections.
Keywords: Acute pancreatitis; Drug resistance; Infection; Multi-drug resistant Pseudomonas aeruginosa; Risk factor.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia.Clin Infect Dis. 2020 Dec 23;71(Suppl 4):S386-S393. doi: 10.1093/cid/ciaa1522. Clin Infect Dis. 2020. PMID: 33367574
-
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.BMC Infect Dis. 2017 Jul 17;17(1):500. doi: 10.1186/s12879-017-2597-0. BMC Infect Dis. 2017. PMID: 28716109 Free PMC article.
-
Impact of carbapenem-resistant Acinetobacter baumannii infections on acute pancreatitis patients.Pancreatology. 2022 Mar;22(2):194-199. doi: 10.1016/j.pan.2021.12.004. Epub 2021 Dec 14. Pancreatology. 2022. PMID: 34924296
-
Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.Antimicrob Resist Infect Control. 2018 Jul 4;7:79. doi: 10.1186/s13756-018-0370-9. eCollection 2018. Antimicrob Resist Infect Control. 2018. PMID: 29997889 Free PMC article.
-
Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms.Curr Opin Infect Dis. 2024 Dec 1;37(6):594-601. doi: 10.1097/QCO.0000000000001044. Epub 2024 Sep 18. Curr Opin Infect Dis. 2024. PMID: 39149832 Free PMC article. Review.
Cited by
-
Impact of invasive infections on clinical outcomes in acute pancreatitis: early predictive factors and implications for prophylactic anti-infective therapy.Gut Pathog. 2025 Jan 19;17(1):5. doi: 10.1186/s13099-024-00671-3. Gut Pathog. 2025. PMID: 39828733 Free PMC article.
-
Characterization of Pancreatic Infections in Patients with Severe Acute Pancreatitis: A Retrospective Study from 2019 to 2023.Infect Drug Resist. 2025 Jan 11;18:199-207. doi: 10.2147/IDR.S500916. eCollection 2025. Infect Drug Resist. 2025. PMID: 39816241 Free PMC article.
-
Risk Factor Analysis and Molecular Epidemiological Investigation of Carbapenem-Resistant Enterobacteriaceae (CRE) Infection in Patients with Acute Pancreatitis.Infect Drug Resist. 2025 Jan 16;18:297-306. doi: 10.2147/IDR.S498829. eCollection 2025. Infect Drug Resist. 2025. PMID: 39835162 Free PMC article.
-
The fatty acid synthesis gene fabY affects lipopolysaccharide synthesis and colistin susceptibility in Pseudomonas aeruginosa.Microbiol Spectr. 2025 Aug 5;13(8):e0133925. doi: 10.1128/spectrum.01339-25. Epub 2025 Jul 15. Microbiol Spectr. 2025. PMID: 40662729 Free PMC article.
-
Effect of the Step-Jump Approach in Infected Pancreatic Necrosis: A Propensity Score-Matched Study.J Inflamm Res. 2024 Sep 5;17:6005-6021. doi: 10.2147/JIR.S461740. eCollection 2024. J Inflamm Res. 2024. PMID: 39253564 Free PMC article.
References
MeSH terms
Substances
Grants and funding
- No. 202106370184/China Scholarship Council
- No. 202106370184/China Scholarship Council
- No. 202106370184/China Scholarship Council
- No. 202106370184/China Scholarship Council
- No. 202106370184/China Scholarship Council
- No. 202106370184/China Scholarship Council
- No. 202106370184/China Scholarship Council
- Grant No. 81670589 and No. 82170661/National Natural Science Foundation of China
- Grant No. 81670589 and No. 82170661/National Natural Science Foundation of China
- Grant No. 81670589 and No. 82170661/National Natural Science Foundation of China
- Grant No. 81670589 and No. 82170661/National Natural Science Foundation of China
- Grant No. 81670589 and No. 82170661/National Natural Science Foundation of China
- Grant No. 81670589 and No. 82170661/National Natural Science Foundation of China
- Grant No. 81670589 and No. 82170661/National Natural Science Foundation of China
LinkOut - more resources
Full Text Sources
Medical